Bevacizumab biosimilar - Allergan/Amgen

Drug Profile

Bevacizumab biosimilar - Allergan/Amgen

Alternative Names: ABP-215

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen; Watson Pharmaceuticals
  • Developer Allergan; Amgen
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Non-small cell lung cancer

Most Recent Events

  • 07 Jun 2017 The US FDA's Oncologic Drugs Advisory Committee schedules a meeting to review the BLA for bevacizumab biosimilar
  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 Feb 2017 Biosimilar User Fee Act (BsUFA) date for Non-small cell lung cancer (Late-stage disease) in USA (IV) is 2017-09-14
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top